U.S. drugmakers are working to ensure that President Barack Obama’s move to encourage cheaper medical care doesn’t end up dictating treatments to doctors and insurers.
“The companies fear that older generic drugs might very well turn out to be better than the newer advertised drugs, which bring in much more of a profit,” said Julian Zelizer, a history and public affairs professor at Princeton University in Princeton, New Jersey. “In difficult economic times, the drug companies don’t want to take any risks, so they are bringing out the biggest lobbyists in the business.”
No comments:
Post a Comment
Thanks for your comment it is much appreciated.